Cargando…
Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial
BACKGROUND: Systemic lupus erythematosus (SLE) is a complex autoimmune disease associated with widespread immune dysregulation and diverse clinical features. Immune abnormalities might be differentially associated with specific organ involvement or response to targeted therapies. We aimed to identif...
Autores principales: | Shipa, Muhammad, Santos, Liliana R, Nguyen, Dao X, Embleton-Thirsk, Andrew, Parvaz, Mariea, Heptinstall, Lauren L, Pepper, Ruth J, Isenberg, David A, Gordon, Caroline, Ehrenstein, Michael R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894756/ https://www.ncbi.nlm.nih.gov/pubmed/36756239 http://dx.doi.org/10.1016/S2665-9913(22)00332-0 |
Ejemplares similares
-
The synergistic efficacy of hydroxychloroquine with methotrexate is accompanied by increased erythrocyte mean corpuscular volume
por: Shipa, Muhammad Ruhul Amin, et al.
Publicado: (2021) -
Follow up study of B-lymphocyte depletion in the treatment of patients with systemic lupus erythematosus
por: Leandro, MJ, et al.
Publicado: (2005) -
Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial
por: Jones, Alexis, et al.
Publicado: (2019) -
Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015) -
SLE is not a one-size-fits-all disease
por: Ehrenstein, Michael R., et al.
Publicado: (2023)